This CME-accredited OncoBlast activity uses case-based scenarios to guide oncology professionals through the diagnosis and management of smoldering and symptomatic multiple myeloma. Learners will review risk stratification, treatment selection, and emerging evidence on induction, maintenance, and supportive care strategies.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Kwan-Keat Ang (MD)
Kwan-Keat Ang, MD is a first-year hematology and oncology fellow at UCSF with an interest in multiple myeloma and plasma cell dyscrasias. His interest in hematologic malignancies derived from a fascination with cancer immunology in which translational work has led to the advancements in technology such as cellular therapy and immunotherapy. He aspires to become a clinical trialist and work amongst his mentors one day, pushing the boundaries of knowledge and delivering novel therapies to help his patients live longer and better lives.
Disclosure
Financial relationships No, I have not had a financial relationship with an ineligible company within the past 24 months.
- Medical oncologists
- Oncology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Target Audience
- Identify and risk-stratify smoldering and active multiple myeloma.
- Select appropriate induction and maintenance therapies based on patient profile and current evidence.
- Recognize and manage treatment-related toxicities associated with novel myeloma agents.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: